blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1791565

EP1791565 - CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.02.2017
Database last updated on 20.05.2024
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990 / US
[2016/16]
Former [2007/23]For all designated states
GENENTECH, INC.
1 DNA Way
South San Francisco, CA 94080-4990 / US
Inventor(s)01 / EIGENBROT, Charles W.
1129 Bernal Avenue
Burlingame, California 94010 / US
02 / JUNUTULA, Jagath Reddy
34391 Tupelo Street
Fremont, California 94555 / US
03 / LOWMAN, Henry
P.O. Box 2556, 400 San Juan Avenue
El Granada, California 94018 / US
04 / RAAB, Helga E.
715 Shields Street
San Francisco, California 94132 / US
05 / VANDLEN, Richard
1015 Hayne Road
Hillsborough, California 94010 / US
 [2007/23]
Representative(s)Kiddle, Simon John, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2016/16]
Former [2007/23]Kiddle, Simon John, et al
Mewburn Ellis LLP York House, 23 Kingsway
London WC2B 6HP / GB
Application number, filing date05811919.922.09.2005
[2007/23]
WO2005US34353
Priority number, dateUS20040612468P23.09.2004         Original published format: US 612468 P
US20050696353P30.06.2005         Original published format: US 696353 P
[2007/23]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006034488
Date:30.03.2006
Language:EN
[2006/13]
Type: A2 Application without search report 
No.:EP1791565
Date:06.06.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 30.03.2006 takes the place of the publication of the European patent application.
[2007/23]
Type: B1 Patent specification 
No.:EP1791565
Date:20.04.2016
Language:EN
[2016/16]
Search report(s)International search report - published on:EP28.09.2006
ClassificationIPC:A61K47/48
[2007/23]
CPC:
A61K47/6803 (EP,US); A61K47/50 (KR); A61K39/395 (KR);
A61K45/06 (EP,US); A61K47/6817 (EP,US); A61K47/6851 (EP,US);
A61K47/6889 (EP,US); A61P35/00 (EP); C07K16/00 (EP,US);
C07K16/32 (EP,US); A01K2267/0331 (EP,US); C07K2317/21 (EP,US);
C07K2317/51 (EP,US); C07K2317/52 (EP,US); C07K2317/55 (EP,US);
C07K2317/624 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/16]
Former [2007/23]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL04.04.2007
BA04.04.2007
HR04.04.2007
MK04.04.2007
YU04.04.2007
TitleGerman:Zystein-modifizierte Antikörper und Konjugate[2016/04]
English:CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES[2007/23]
French:ANTICORPS ET CONJUGUES PRODUITS AVEC DE LA CYSTEINE[2007/23]
Former [2007/23]MIT CYSTEIN MANIPULIERTE ANTIKÖRPER UND KONJUGATE
Entry into regional phase04.04.2007National basic fee paid 
04.04.2007Designation fee(s) paid 
04.04.2007Examination fee paid 
Examination procedure04.04.2007Examination requested  [2007/23]
28.05.2008Despatch of a communication from the examining division (Time limit: M06)
18.09.2008Reply to a communication from the examining division
19.05.2010Despatch of a communication from the examining division (Time limit: M04)
27.09.2010Reply to a communication from the examining division
17.04.2012Despatch of a communication from the examining division (Time limit: M04)
02.05.2012Reply to a communication from the examining division
25.11.2013Despatch of a communication from the examining division (Time limit: M06)
03.06.2014Reply to a communication from the examining division
07.08.2015Communication of intention to grant the patent
25.02.2016Communication of intention to grant the patent
26.02.2016Receipt of the translation of the claim(s)
03.03.2016Fee for grant paid
03.03.2016Fee for publishing/printing paid
Divisional application(s)EP16158429.7  / EP3088004
EP18157413.8
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.05.2008
Opposition(s)23.01.2017No opposition filed within time limit [2017/13]
Fees paidRenewal fee
12.09.2007Renewal fee patent year 03
15.09.2008Renewal fee patent year 04
11.09.2009Renewal fee patent year 05
14.09.2010Renewal fee patent year 06
29.09.2011Renewal fee patent year 07
12.09.2012Renewal fee patent year 08
09.09.2013Renewal fee patent year 09
08.09.2014Renewal fee patent year 10
08.09.2015Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG20.04.2016
CY20.04.2016
EE20.04.2016
FI20.04.2016
IS20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
RO20.04.2016
SK20.04.2016
GR21.07.2016
PT22.08.2016
LU22.09.2016
[2018/38]
Former [2018/33]CY20.04.2016
EE20.04.2016
FI20.04.2016
IS20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
RO20.04.2016
SK20.04.2016
GR21.07.2016
PT22.08.2016
LU22.09.2016
Former [2018/29]CY20.04.2016
EE20.04.2016
FI20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
RO20.04.2016
SK20.04.2016
GR21.07.2016
PT22.08.2016
LU22.09.2016
Former [2017/47]EE20.04.2016
FI20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
RO20.04.2016
SK20.04.2016
GR21.07.2016
PT22.08.2016
LU22.09.2016
Former [2017/31]EE20.04.2016
FI20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
RO20.04.2016
SK20.04.2016
GR21.07.2016
PT22.08.2016
Former [2017/10]EE20.04.2016
FI20.04.2016
LT20.04.2016
LV20.04.2016
RO20.04.2016
SK20.04.2016
GR21.07.2016
PT22.08.2016
Former [2016/51]FI20.04.2016
LT20.04.2016
LV20.04.2016
GR21.07.2016
PT22.08.2016
Former [2016/49]FI20.04.2016
LT20.04.2016
Former [2016/46]LT20.04.2016
Cited inInternational search[X]WO9406474  (GALAGEN INC [US]) [X] 13 * page 32 - page 34 *;
 [X]WO03049704  (UNIV MASSACHUSETTS [US], et al) [X] 2,6-8,18-36,38-46,57-96 * page 24 *;
 [X]WO03060080  (IDEXX LAB INC [US], et al) [X] 11 * page 91 *;
 [X]WO2004050849  (US GOV HEALTH & HUMAN SERV [US], et al) [X] 2-4 * page 45 *;
 [X]  - SHOPES B, "A GENETICALLY ENGINEERED HUMAN IGG WITH LIMITED FLEXIBILITY FULLY INITIATES CYTOLYSIS VIA COMPLEMENT", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, (1993), vol. 30, no. 6, ISSN 0161-5890, pages 603 - 609, XP009047992 [X] 2,3 * page 608 *

DOI:   http://dx.doi.org/10.1016/0161-5890(93)90035-A
 [A]  - HAFNER F T ET AL, "Noncompetitive immunoassay of small analytes at the femtomolar level by affinity probe capillary electrophoresis: direct analysis of digoxin using a uniform-labeled scFv immunoreagent.", ANALYTICAL CHEMISTRY. 1 DEC 2000, (20001201), vol. 72, no. 23, ISSN 0003-2700, pages 5779 - 5786, XP002392218 [A] * page 5780 *

DOI:   http://dx.doi.org/10.1021/ac000853+
 [X]  - RENARD M ET AL, "Deriving Topological Constraints from Functional Data for the Design of Reagentless Fluorescent Immunosensors", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20030207), vol. 326, no. 1, ISSN 0022-2836, pages 167 - 175, XP004450025 [X] 2,40-43 * page 168 - page 169 *

DOI:   http://dx.doi.org/10.1016/S0022-2836(02)01334-7
 [X]  - CORNEILLIE TODD M ET AL, "Converting weak binders into infinite binders.", BIOCONJUGATE CHEMISTRY. 2004 NOV-DEC, (200406), vol. 15, no. 6, ISSN 1043-1802, pages 1389 - 1391, XP002392219 [X] 57-110 * page 1389 - page 1390 *

DOI:   http://dx.doi.org/10.1021/bc049825e
 [A]  - TRAIL PAMELA A ET AL, "Monoclonal antibody drug immunoconjugates for targeted treatment of cancer.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII. MAY 2003, (200305), vol. 52, no. 5, ISSN 0340-7004, pages 328 - 337, XP002392220 [A] 60-96 * the whole document *
 [A]  - SCHELTE P ET AL, "TECHNICAL NOTES. DIFFERENTIAL REACTIVITY OF MALEIMIDE AND BROMOACETYL FUNCTIONS WITH THIOLS: APPLICATION TO THE PREPARATION OF LIPOSOMAL DIEPITOPE CONSTRUCTS", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, (200001), vol. 11, no. 1, ISSN 1043-1802, pages 118 - 123, XP000887774 [A] 1 * abstract *

DOI:   http://dx.doi.org/10.1021/bc990122k
Examination   - LYONS A ET AL, "SITE-SPECIFIC ATTACHMENT TO RECOMBINANT ANTIBODIES VIA INTRODUCED SURFACE CYSTEINE RESIDUES", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, (19900101), vol. 3, no. 8, ISSN 0269-2139, pages 703 - 708, XP001000052
    - WRIGHT S K ET AL, "Evaluation of methods for the quantitation of cysteines in proteins.", ANALYTICAL BIOCHEMISTRY 1 DEC 1998 LNKD- PUBMED:9866701, (19981201), vol. 265, no. 1, ISSN 0003-2697, pages 8 - 14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.